芳香酶抑制剂（AI）可以提高身材矮小的情况下的身高；然而，对儿童癌症幸存者（CCS）的影响尚不清楚。我们评估了接受 AI 和 GH 治疗的 CCS 与仅接受 GH 治疗的 CCS 的最终成年身高 (FAH)。对 2007 年至 2023 年间接受 GH 缺乏的男性 CCS 进行回顾性队列研究。FAH 被记录为生长板融合处的身高或 18 岁。使用多变量线性回归来检查治疗与 FAH 的关联，并调整其他危险因素。共纳入 92 名患者； 70 名患者接受 GH 治疗，22 名患者接受 AI/GH 联合治疗。开始 GH 时的平均年龄在各组之间没有差异。开始 AI 时的平均年龄为 13.7 ± 1.9 岁。 AI/GH 组中较大比例的患者接受干细胞移植、腹部放射、全身放射和顺式视黄酸治疗 (p < .01)。多变量线性回归表明治疗与 FAH Z 评分没有显着相关性（β = 0.04，95% CI：-0.9 至 0.9）。脊柱放射史（β = -0.93，95% CI：-1.7 至 -0.2），起始高度 Z 分数较低（β = -0.8，95% CI：-1.2 至 -0.4），骨龄差异较大年龄（β = -0.3，95% CI：-0.5 至 -0.07）与较低的 FAH Z 评分相关。与 GH 单药治疗相比，辅助 AI 与男性 CCS 中 FAH 的增加无关。未来需要开展工作来确定最佳辅助治疗，以最大限度地提高该人群的 FAH。© 2024 Wiley periodicals LLC。

Aromatase inhibitors (AI) may improve height in short stature conditions; however, the effect in childhood cancer survivors (CCS) is unknown. We assessed final adult height (FAH) in CCS treated with AI and GH compared with those treated with GH alone.Retrospective cohort study of GH-deficient male CCS treated between 2007 and 2023. FAH was noted as the height at the fusion of growth plates or 18 years of age. Multivariable linear regression was used to examine treatment association with FAH, adjusting for other risk factors.Ninety-two patients were included; 70 were treated with GH and 22 with combination AI/GH. The mean age at GH initiation did not differ between groups. The mean age at AI initiation was 13.7 ± 1.9 years. A greater proportion of patients in the AI/GH group were treated with stem cell transplantation, abdominal radiation, total body irradiation, and cis-retinoic acid (p < .01). Multivariable linear regression demonstrated no significant treatment association with FAH Z-score (β = 0.04, 95% CI: -0.9 to 0.9). History of spinal radiation (β = -0.93, 95% CI: -1.7 to -0.2), lower starting height Z-score (β = -0.8, 95% CI: -1.2 to -0.4), and greater difference between bone age and chronological age (β = -0.3, 95% CI: -0.5 to -0.07) were associated with lower FAH Z-score.Adjuvant AI was not associated with increased FAH in male CCS compared with GH monotherapy. Future work is needed to determine the optimal adjunctive treatment to maximize FAH for this population.© 2024 Wiley Periodicals LLC.